European Heart Journal Advance Access originally published online on July 19, 2005
European Heart Journal 2005 26(16):1571-1572; doi:10.1093/eurheartj/ehi428
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
Gender-specific prescription for cardiovascular diseases?
1Department of Cardiology, Istituto Auxologico Italiano IRCCS, Milan, Italy
2Molecular Cardiology, IRCCS Fondazione Maugeri, University of Pavia, Via Ferrata 8, 27100 Pavia, Italy
3Department of Cardiology, University of Pavia, Pavia, Italy
* Corresponding author. Fax: +39 0382 592059. E-mail address: spriori@fsm.it
This editorial refers to Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases
by N. Jochmann et al., on page 1585
| The first 10% of the full text of this article appears below. |
The interest of the scientific and medical community on the impact of cardiovascular diseases in women has significantly grown in the last few years. Cardiovascular disease is indeed the leading cause of death among both women and men, even if this unequivocal epidemiological observation had not been taken into the right consideration in the past. Although cardiovascular diseases are equally important in men and women, gender differences in the clinical manifestation and progression of the disease have been demonstrated. The understanding of these differences is of crucial importance for the improvement of the clinical management of cardiovascular diseases and for the development of possible new gender-specific diagnostic and therapeutic options.
Women, for many years, have been underrepresented in randomized clinical trials and only recently there has been a significant increase in the number and proportion of women who participate in these studies. Accordingly, the possibility of different
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases
- Nicoline Jochmann, Karl Stangl, Edeltraut Garbe, Gert Baumann, and Verena Stangl
EHJ 2005 26: 1585-1595.[Abstract] [Full Text]
This article has been cited by other articles:
![]() |
Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF] |
||||
![]() |
P. Collins, G. Rosano, C. Casey, C. Daly, M. Gambacciani, P. Hadji, R. Kaaja, T. Mikkola, S. Palacios, R. Preston, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists Eur. Heart J., August 2, 2007; 28(16): 2028 - 2040. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Genovesi, D. Zaccaria, E. Rossi, M. G. Valsecchi, A. Stella, and M. Stramba-Badiale Effects of exercise training on heart rate and QT interval in healthy young individuals: are there gender differences? Europace, January 1, 2007; 9(1): 55 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stramba-Badiale, K. M. Fox, S. G. Priori, P. Collins, C. Daly, I. Graham, B. Jonsson, K. Schenck-Gustafsson, and M. Tendera Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology Eur. Heart J., April 2, 2006; 27(8): 994 - 1005. [Abstract] [Full Text] [PDF] |
||||

